Researcher.Life Logo

Oncology and Therapy : Impact Factor & More

eISSN: 2366-1089pISSN: 2366-1070
JournalOpen Access

Key Metrics

CiteScore
0.3
H-Index
5
SJR
Q2Oncology
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Oncology and Therapy

Oncology and Therapy Journal Specifications

Overview
Publisher SPRINGER
Language English
Frequency Semi-annual
Article Processing ChargesEUR 4500 | USD 5600 | GBP 4100
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencySemi-annual
Publication Start Year2016
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Oncology and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Oncology and Therapy

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine KinaseInhibitors for Treatment-Naïve CLL.
  • 22 Jun 2026
  • Oncology and therapy
Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.
  • 21 Jun 2026
  • Oncology and therapy
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.
  • 11 Jun 2026
  • Oncology and therapy
Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
  • 9 Jun 2026
  • Oncology and therapy
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.
  • 5 Jun 2026
  • Oncology and therapy
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia.
  • 1 Jun 2026
  • Oncology and therapy
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine KinaseInhibitors for Treatment-Naïve CLL.
  • 22 Jun 2026
  • Oncology and therapy
Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.
  • 21 Jun 2026
  • Oncology and therapy
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.
  • 11 Jun 2026
  • Oncology and therapy
Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
  • 9 Jun 2026
  • Oncology and therapy
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.
  • 5 Jun 2026
  • Oncology and therapy
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia.
  • 1 Jun 2026
  • Oncology and therapy

FAQs on Oncology and Therapy